The effect of dapagliflozin on triglyceride glucose index (TyG) in atherosclerotic coronary artery disease

The effect of dapagliflozin on triglyceride glucose index (TyG) in outpatients with atherosclerotic coronary artery disease and TyG greater than 8.44

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250315065073N1

Enrollment

Registered

2025-04-16

Start date

2025-05-05

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerotic coronary artery disease. Atherosclerotic heart disease of native coronary artery

Interventions

Intervention 1: Intervention group: Dapagliflozin10 mg (Gloxiga - Modava Company), one film coated tablet orally daily , for 12 weeks. Intervention 2: Control group: Placebo, film coated tablet with a

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: atherosclerotic coronary artery disease TyG index greater than 8.44 Stable clinical condition At least three months since diagnosis

Exclusion criteria

Exclusion criteria: Type I or II Diabetes or Prediabetes Heart failure with preserved or reduced EF Atrial or Ventricular Arrhythmia Pulmonary hypertension Familial hypertriglyceridemia Contraindications to taking the drug (including history of ketoacidosis, malignancy, renal or hepatic failure, osteoporosis, vasovagal syncope, seizures, hypoglycemia, genitourinary tract disease, significant pulmonary disease, recurrent UTI, urosepsis, significant peripheral vascular disease) Pregnancy, breastfeeding or intending to get pregnant bariatric surgery or malabsorption disorder Use of SGLT2 inh drugs within the last three months or allergy to these drugs BMI greater than 45 kg/m2 Use of TG-lowering drugs (fibrates, niacin), corticosteroids, hypoglycemic drugs, antipsychotic drugs, MAO, lithium, androgens Chronic alcohol consumption Anemia (Hemoglobulin level less than 9 mg/dl)

Design outcomes

Primary

Measure	Time frame
Triglyceride Glucose Index (TyG). Timepoint: 12 weeks. Method of measurement: Laboratory examination of blood sample.	—

Secondary

Measure	Time frame
Lipid profile (HDL, LDL, Chol). Timepoint: 12 weeks. Method of measurement: Laboratory examination of blood sample.;Hb A1c. Timepoint: 12 weeks. Method of measurement: Laboratory examination of blood sample.;Waist circumference. Timepoint: 12 weeks. Method of measurement: Measurement by a trained and blinded person.;Body mass index. Timepoint: 12 weeks. Method of measurement: Measurement by a trained and blinded person.	—

Measure

Time frame

Lipid profile (HDL, LDL, Chol). Timepoint: 12 weeks. Method of measurement: Laboratory examination of blood sample.;Hb A1c. Timepoint: 12 weeks. Method of measurement: Laboratory examination of blood sample.;Waist circumference. Timepoint: 12 weeks. Method of measurement: Measurement by a trained and blinded person.;Body mass index. Timepoint: 12 weeks. Method of measurement: Measurement by a trained and blinded person.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir mohammad Beyki

Tehran University of Medical Sciences

am-beyki@razi.tums.ac.ir+98 21 7783 5954

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026